Yahoo Web Search

  1. Today's Daily Dose brings you news about AstraZeneca's phase I/II study evaluating Acalabrutinib alone and in combination in chronic lymphocytic leukemia; bluebird's update on LentiGlobin ...

  2. Poster presentations on preclinical data for IMGN779 in combination with cytarabine and...

  3. Patients with leukemia who were transfusion dependent had a hospice stay that was about half as short as that in patients with leukemia who were not receiving blood transfusions ...

  4. The open-label, randomized, multi-center clinical study, evaluated eryaspase in newly diagnosed AML patients over the age of 65 and unfit for intensive chemotherapy. The study enrolled a total ...

  5. Shares of Bluebird Bio BLUE were up nearly 20% in early morning trading Monday as investors responded to the company’s announcement that its CAR-T candidate, bb2121, produced encouraging results ...

  6. MOVERS: (+) BLUE (+30.18%) Phase 1 study of bb2121 with Celgene ( CELG ) showed 94% response rate (+) AKTX (+12.04%) Phase II COBALT trial met its primary endpoint (+) VSTM (+8.78%) Leukemia ...

  7. As a kid in Crosby, Tex., she watched her best friend grow ill with leukemia. When the 7-year-old died, Joyal didn't think much about her friend's parents.

  8. "I have multiple myeloma, which is a blood cancer like lymphoma or leukemia, but it's considered terminal," said Craig Finkbeiner, cancer patient. "It's important to me because then they ...

  9. Philip Serlin, Chief Executive Officer of BioLineRx, stated, "This annual event gives us the opportunity to directly meet with our investors for updates on our progress: steady advancements ...

  10. University of North Carolina Lineberger Comprehensive Cancer Center scientists have developed a software program that can accurately predict which tumor-specific markers will show up on the ...

  1. 12345584 results